Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

New guideline recommends proper preconception care for women with diabetes

A joint guideline released today from the Endocrine Society and the European Society of Endocrinology (ESE) recommends women with diabetes receive proper preconception care and access to emerging diabetes technology and therapeutics to manage their blood sugar before, during and after pregnancy.

13 Jul 2025

Higher protein intake may help prevent muscle loss in semaglutide users

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Combining tirzepatide and hormone therapy boosts weight loss in postmenopausal women

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Tirzepatide reduces obesity-associated breast cancer growth in mouse model

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Innovative genome editing approach could be the key to lifelong effective weight management

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.

9 Jul 2025

New study identifies factors linked to successful weight loss using GLP-1RAs

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).

9 Jul 2025

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.

7 Jul 2025

Uterine cancer deaths expected to rise sharply in the United States by 2050

Uterine cancer incidence and mortality rates are projected to increase significantly over the next three decades in the United States, with incidence-based mortality expected to be nearly three times higher in Black women compared with white women by 2050.

1 Jul 2025

$Newer, more effective diabetes drugs reach only a fraction of patients$

Newer, more effective diabetes drugs reach only a fraction of patients

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

1 Jul 2025

Glycogen metabolism in neurons emerges as key to fighting Alzheimer's

A new study from scientists at the Buck Institute for Research on Aging has revealed a surprising player in the battle against Alzheimer's disease and other forms of dementia: brain sugar metabolism.

1 Jul 2025

Coffee’s hidden compounds could help fight type 2 diabetes

A comprehensive review of nearly 150 studies reveals that coffee polyphenols may help regulate blood sugar and reduce inflammation linked to type 2 diabetes. However, most evidence comes from preclinical research, and robust clinical trials are needed to confirm benefits.

29 Jun 2025

Tummy tuck patients continue losing weight years after surgery

Most patients undergoing "tummy tuck" surgery (abdominoplasty) to remove excess skin and tissue after weight loss continue to lose weight in the months and years after surgery, suggests a follow-up study in the July issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

26 Jun 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

New guidance helps GPs manage patients using weight loss drugs

Academics at King's College London and the University of East Anglia have released guidance for GPs on how to manage patients who may be privately accessing weight loss drugs.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Experimental drug promotes weight loss by heating fat instead of suppressing appetite

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss.

24 Jun 2025

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

23 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025